XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2018
Japan [Member] |
Summary of Revenue Recognized under Agreement | Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):
|  |  |  | Three Months Ended March 31, |
Agreement |  | Performance Obligation |  | 2018 |  |  | 2017 * |
Japan |  | License revenue |  | $ | — |  |  | $ | — |
|  | Development revenue |  | $ | 449 |  |  | $ | 296 |
* | Recast to reflect the adoption of the new revenue standards. See Note 1.
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue | The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):
|  | Cumulative Revenue Through March 31, 2018 |  |  | Deferred Revenue at March 31, 2018 |  |  | Total Consideration Through March 31, 2018 |
License |  | $ | 59,766 |  |  | $ | — |  |  | $ | 59,766 |
Manufacturing--clinical supplies |  |  | 11,957 |  |  |  | 436 |  |  |  | 12,393 |
Total license and development revenue |  | $ | 71,723 |  |  | $ | 436 |  |  | $ | 72,159 |
Europe [Member] |
Summary of Revenue Recognized under Agreement | Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):
|  |  |  | Three Months Ended March 31, |
Agreement |  | Performance Obligation |  | 2018 |  |  | 2017 * |
Europe |  | License revenue |  | $ | — |  |  | $ | — |
|  | Development revenue |  | $ | 4,723 |  |  | $ | 4,390 |
* | Recast to reflect the adoption of the new revenue standards. See Note 1.
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue | The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):
|  | Cumulative Revenue Through March 31, 2018 |  |  | Deferred Revenue at March 31, 2018 |  |  | Total Consideration Through March 31, 2018 |
License |  | $ | 370,481 |  |  | $ | — |  |  | $ | 370,481 |
Manufacturing--clinical supplies |  |  | 189,056 |  |  |  | 6,101 |  |  |  | 195,157 |
Total license and development revenue |  | $ | 559,537 |  |  | $ | 6,101 |  |  | $ | 565,638 |
U.S./RoW and China [Member] |
Summary of Revenue Recognized under Agreement | Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):
|  |  |  | Three Months Ended March 31, |
Agreement |  | Performance Obligation |  | 2018 |  |  | 2017 * |
U.S. / RoW and China |  | License revenue |  | $ | — |  |  | $ | — |
|  | Development revenue |  |  | 26,723 |  |  |  | 24,756 |
|  | China performance obligation |  | $ | — |  |  | $ | — |
* | Recast to reflect the adoption of the new revenue standards. See Note 1.
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue | The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):
|  | Cumulative Revenue Through March 31, 2018 |  |  | Deferred Revenue at March 31, 2018 |  |  | Total Consideration Through March 31, 2018 |
License |  | $ | 286,216 |  |  | $ | — |  |  | $ | 286,216 |
Co-development, information sharing & committee services |  |  | 330,391 |  |  |  | 36,360 |  |  |  | 366,751 |
China performance obligation |  |  | — |  |  |  | 112,009 |  |  |  | 112,009 |
Total license and development revenue |  | $ | 616,607 |  |  | $ | 148,369 |  |  | $ | 764,976 |

X
- Definition Tabular disclosure of the recognition of revenue by the different types of revenue under a collaboration agreement. + References No definition available. + Details
Name: | fgen_RevenueRecognitionByTypeTableTextBlock
Namespace Prefix: | fgen_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68059916&loc=d3e50766-111635 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635 + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |